A graph on a white background

Description automatically generated

**Appendix Figure 1:** Overall Survival in Patients Treated with Atezolizumab with Bevacizumab Stratified by

(**A)** ALBI grade (**B)** Liver etiology and (**C)** Portal vein tumor thrombosis

A graph of a number of numbers

Description automatically generated with medium confidence**Appendix Figure 2:** Progression-Free Survival in Patients Treated with Atezolizumab with Bevacizumab Stratified by **A)** ALBI grade **B)** Liver etiology and **C)** Portal vein tumor thrombosis

**Appendix Table 1**: Impact of clinical characteristics on bleeding risk.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Bleeding events** | |  |
| **Characteristic** | **Total included** | **No (n = 95)** | **Yes (n= 17)** | **p-value** |
| **Cirrhosis** | 75 (67.0%) | 64 (67.4%) | 11 (64.7%) | 0.83 |
|  |  |  |  |  |
| **Hepatitis B** | 28 (25.0%) | 20 (21.1%) | 8 (47.1%) | **0.03** |
| **Hepatitis C** | 37 (33.0%) | 32 (33.7%) | 5 (29.4%) | 0.73 |
| **NASH** | 17 (15.2%) | 13 (13.7%) | 4 (23.5%) | 0.29 |
| **Excess alcohol use** | 25 (22.3%) | 24 (25.3%) | 1 (5.9%) | 0.11 |
|  |  |  |  |  |
| **Prior locoregional treatment** |  |  |  |  |
| **TACE procedures** | 29 |  |  |  |
| 0 | 83 (74.1%) | 71 (74.7%) | 12 (70.6%) |  |
| 1 | 11 (9.8%) | 10 (10.5%) | 1 (5.9%) | 1.00 |
| 2 | 14 (12.5%) | 13 (13.7%) | 1 (5.9%) | 0.72 |
| 3 | 4 (3.6%) | 1 (1.1%) | 3 (17.6%) | **0.03** |
| **Radiofrequency Ablation** | 33 (29.5%) | 28 (29.5%) | 5 (29.4%) | 1.00 |
| **Stereotactic Body Radiation Therapy** | 17 (21.8%) | 15 (23.1%) | 2 (15.4%) | 0.72 |
| **Liver resection** | 29 (25.9%) | 22 (23.2%) | 7 (41.2%) | 0.14 |
| **Liver transplant** | 1 (0.9%) | 0 (0.0%) | 1 (5.9%) | 0.15 |
|  |  |  |  |  |
| **Macrovascular invasion** | 41 (36.9%) | 35 (37.2%) | 6 (35.3%) | 0.88 |
| Unknown | 1 | 1 | 0 |  |
|  |  |  |  |  |
| **Tumor size** | 96 |  |  | 0.56 |
| Mean ± SD | 5.8 ± 4.7 | 5.7 ± 4.8 | 6.0 ± 4.3 |  |
| Median (Range) | 3.8 (0.0, 18.0) | 3.8 (0.0, 18.0) | 6.0 (0.0, 15.6) |  |
| Unknown | 16 | 16 | 0 |  |
|  |  |  |  |  |
| **Tumor Histology** | 76 |  |  | **0.04** |
| HCC | 73 (96.1%) | 66 (98.5%) | 7 (77.8%) |  |
| Mixed CCA-HCC | 3 (3.9%) | 1 (1.5%) | 2 (22.2%) |  |
| Unknown | 36 | 28 | 8 |  |
|  |  |  |  |  |

NASH: non-alcoholic steatohepatitis; TACE: Transarterial Chemoembolization; SD: standard deviation; HCC: hepatocellular carcinoma; CCA: cholangiocarcinoma.